[ Tips ] 一分鐘使用導覽
商品編號： 9-218-094 出版日期： 2018/03/21 作者姓名： Baker, Malcolm P.;McComb, Emily R. 商品類別： Finance 商品規格： 17p 再版日期： 地域： 產業： Biotechnology 個案年度： -
商品敘述：
In February 2011, Adam Koppel, a Managing Director at Brookside Capital, the public equity arm of Bain Capital, must decide whether to increase or exit the firm''s position in Celgene Corporation. News has emerged that raises potential safety concerns associated with Celgene''s key drug, Revlimid. In response, Celgene''s share price has traded down 20% in the last two months, and is now almost 10% below the level where Brookside made their initial investment.
涵蓋領域：
Decision making;Finance;Growth;Hedge funds;Investments;Stocks;Valuation
相關資料：
Spreadsheet Supplement, (9-218-743), 0p, by Malcolm P. Baker, Emily R. McComb
哪些人也有訂購？